Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies

被引：14

作者：

Ambrosini, Giulia ^{[1
]}

Cordani, Marco ^{[2
,3
]}

Zarrabi, Ali ^{[4
,5
]}

Alcon-Rodriguez, Sergio ^{[6
,7
,8
]}

Sainz, Rosa M. ^{[6
,7
,8
]}

Velasco, Guillermo ^{[2
,3
]}

Gonzalez-Menendez, Pedro ^{[6
,7
,8
]}

Dando, Ilaria ^{[1
]}

机构：

[1] Univ Verona, Dept Neurosci Biomed & Movement Sci, I-37134 Verona, Italy

[2] Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol, Madrid 28040, Spain

[3] Inst Invest Sanit San Carlos IdISSC, Madrid 28040, Spain

[4] Istinye Univ, Fac Engn & Nat Sci, Dept Biomed Engn, TR-34396 Istanbul, Turkiye

[5] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci, Dept Res Analyt, Chennai 600077, India

[6] Sch Med, Dept Morfol & Biol Celular, Julian Claveria 6, Oviedo 33006, Spain

[7] Univ Oviedo, Inst Univ Oncol Principado Asturias IUOPA, Oviedo 33006, Spain

[8] Hosp Univ Cent Asturias HUCA, Inst Invest Sanit Principado Asturias ISPA, Oviedo 33011, Spain

来源：

CELL COMMUNICATION AND SIGNALING | 2024年 / 22卷 / 01期

关键词：

Prostate cancer; Oncometabolites; Epigenetic alterations; Cancer stem cells (CSCs); Metabolic Enzymes; EMT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN SEMINAL FLUID; ANDROGEN RECEPTOR; TGF-BETA; STROMAL FIBROBLASTS; SUPPRESSOR-CELLS; REACTIVE STROMA; GENE-EXPRESSION; GROWTH; METABOLISM;

D O I：

10.1186/s12964-023-01462-0

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Prostate cancer, as one of the most prevalent malignancies in males, exhibits an approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events and mutations, including the accumulation of oncometabolites, underpin the genesis and progression of this cancer type. Despite growing research demonstrating the pivotal role of oncometabolites in supporting various cancers, including prostate cancer, the root causes of their accumulation, especially in the absence of enzymatic mutations, remain elusive. Consequently, identifying a tangible therapeutic target poses a formidable challenge. In this review, we aim to delve deeper into the implications of oncometabolite accumulation in prostate cancer. We center our focus on the consequential epigenetic alterations and impacts on cancer stem cells, with the ultimate goal of outlining novel therapeutic strategies.

引用

页数：22

共 209 条

[21] Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model [J].

Chen, H-W ;

Chang, Y-F ;

Chuang, H-Y ;

Tai, W-T ;

Hwang, J-J .

PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (03) :260-264

[22] Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics [J].

Chen, Hongsai ;

Zhu, Weidong ;

Li, Xiye ;

Xue, Lu ;

Wang, Zhaoyan ;

Wu, Hao .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (06) :953-960

[23] Tumor Microenvironment and Metabolism in Prostate Cancer [J].

Chiarugi, Paola ;

Paoli, Paolo ;

Cirri, Paolo .

SEMINARS IN ONCOLOGY, 2014, 41 (02) :267-280

[24] The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer [J].

Choi, Stephen Yiu Chuen ;

Xue, Hui ;

Wu, Rebecca ;

Fazli, Ladan ;

Lin, Dong ;

Collins, Colin C. ;

Gleave, Martin E. ;

Gout, Peter W. ;

Wang, Yuzhuo .

CLINICAL CANCER RESEARCH, 2016, 22 (11) :2721-2733

[25] The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases [J].

Chowdhury, Rasheduzzaman ;

Yeoh, Kar Kheng ;

Tian, Ya-Min ;

Hillringhaus, Lars ;

Bagg, Eleanor A. ;

Rose, Nathan R. ;

Leung, Ivanhoe K. H. ;

Li, Xuan S. ;

Woon, Esther C. Y. ;

Yang, Ming ;

McDonough, Michael A. ;

King, Oliver N. ;

Clifton, Ian J. ;

Klose, Robert J. ;

Claridge, Timothy D. W. ;

Ratcliffe, Peter J. ;

Schofield, Christopher J. ;

Kawamura, Akane .

EMBO REPORTS, 2011, 12 (05) :463-469

[26] Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis [J].

Cirne, Filipe ;

Kappel, Coralea ;

Zhou, Shijie ;

Mukherjee, Som D. ;

Dehghan, Mahshid ;

Petropoulos, Jo-Anne ;

Leong, Darryl P. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (03) :453-462

[27] Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression [J].

Clos-Garcia, Marc ;

Loizaga-Iriarte, Ana ;

Zuniga-Garcia, Patricia ;

Sanchez-Mosquera, Pilar ;

Rosa Cortazar, Ana ;

Gonzalez, Esperanza ;

Torrano, Veronica ;

Alonso, Cristina ;

Perez-Cormenzana, Miriam ;

Ugalde-Olano, Aitziber ;

Lacasa-Viscasillas, Isabel ;

Castro, Azucena ;

Royo, Felix ;

Unda, Miguel ;

Carracedo, Arkaitz ;

Falcon-Perez, Juan M. .

JOURNAL OF EXTRACELLULAR VESICLES, 2018, 7 (01)

[28] Prospective identification of tumorigenic prostate cancer stem cells [J].

Collins, AT ;

Berry, PA ;

Hyde, C ;

Stower, MJ ;

Maitland, NJ .

CANCER RESEARCH, 2005, 65 (23) :10946-10951

[29] Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression [J].

Consiglio, Camila R. ;

Udartseva, Olga ;

Ramsey, Kimberly D. ;

Bush, Chioma ;

Gollnick, Sandra O. .

CANCER IMMUNOLOGY RESEARCH, 2020, 8 (09) :1215-1227

[30] HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment [J].

Corzo, Cesar A. ;

Condamine, Thomas ;

Lu, Lily ;

Cotter, Matthew J. ;

Youn, Je-In ;

Cheng, Pingyan ;

Cho, Hyun-Il ;

Celis, Esteban ;

Quiceno, David G. ;

Padhya, Tapan ;

McCaffrey, Thomas V. ;

McCaffrey, Judith C. ;

Gabrilovich, Dmitry I. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (11) :2439-2453

← 1 2 3 4 5 6 7 8 9 10 →